S101
S101 is an inhibitor of SLP-76 and AhR. By inhibiting SLP-76 phosphorylation, S101 blocks the TCR signaling pathway and prevents AhR nuclear translocation, thereby selectively suppressing the proliferation of activated T cells, inducing their apoptosis, and reducing TNF-α levels. S101 can be used in studies of graft rejection, psoriasis, and superantigen-induced toxic shock.
For research use only. We do not sell to patients.
- CAS No.: 362508-67-6
- Formula: C24H23N3O3
- Molecular Weight:401.47
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
SLP-76 |
AhR |
TNF-α |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PBMC | IC50 |
70 nM
|
Antiproliferative activity against human PBMC assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with stimulated cells.
Antiproliferative activity against human PBMC assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with stimulated cells.
|
20674367 |
| Jurkat | IC50 |
29 nM
|
Antiproliferative activity against human Jurkat acute T cell leukemia cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with stimulated cells.
Antiproliferative activity against human Jurkat acute T cell leukemia cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with stimulated cells.
|
20674367 |
| Jurkat | IC50 |
0.05 μM
|
Antiproliferative activity against human Jurkat acute T cell leukemia cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with non-stimulated cells.
Antiproliferative activity against human Jurkat acute T cell leukemia cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with non-stimulated cells.
|
20674367 |
| PBMC | IC50 |
0.05 μM
|
Antiproliferative activity against human PBMC assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with non-stimulated cells.
Antiproliferative activity against human PBMC assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with non-stimulated cells.
|
20674367 |
| PC-3 | IC50 |
10 μM
|
Antiproliferative activity against human PC3 prostate cancer cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with non-stimulated cells.
Antiproliferative activity against human PC3 prostate cancer cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with non-stimulated cells.
|
20674367 |
| HEK293 | IC50 |
10 μM
|
Antiproliferative activity against human HEK293 embryonic kidney cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with non-stimulated cells.
Antiproliferative activity against human HEK293 embryonic kidney cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with non-stimulated cells.
|
20674367 |
| NIH3T3 | IC50 |
3 μM
|
Antiproliferative activity against mouse NIH 3T3 embryo fibroblasts assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with non-stimulated cells.
Antiproliferative activity against mouse NIH 3T3 embryo fibroblasts assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with non-stimulated cells.
|
20674367 |
| MDA-MB-231 | IC50 |
10 μM
|
Antiproliferative activity against human MDA-MB-231 breast adenocarcinoma cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with non-stimulated cells.
Antiproliferative activity against human MDA-MB-231 breast adenocarcinoma cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with non-stimulated cells.
|
20674367 |
| Jurkat | IC50 |
0.1 μM
|
Antiproliferative activity against human Jurkat acute T cell leukemia cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with stimulated cells.
Antiproliferative activity against human Jurkat acute T cell leukemia cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with stimulated cells.
|
20674367 |
| A-375 | IC50 |
10 μM
|
Antiproliferative activity against human A375 malignant melanoma cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with stimulated cells.
Antiproliferative activity against human A375 malignant melanoma cells assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with stimulated cells.
|
20674367 |
| NIH3T3 | IC50 |
7 μM
|
Antiproliferative activity against mouse NIH 3T3 embryo fibroblasts assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with stimulated cells.
Antiproliferative activity against mouse NIH 3T3 embryo fibroblasts assessed via BrdU incorporation colorimetric ELISA after 72 h incubation with stimulated cells.
|
20674367 |
| PBMC | IC50 |
0.1 μM
|
Antiproliferative activity against human PBMC stimulated with ConA assessed via BrdU incorporation colorimetric ELISA after 72 h incubation.
Antiproliferative activity against human PBMC stimulated with ConA assessed via BrdU incorporation colorimetric ELISA after 72 h incubation.
|
20674367 |
| PBMC | IC50 |
0.5 μM
|
Antiproliferative activity against human PBMC stimulated with ODN2006 or LPS assessed via BrdU incorporation colorimetric ELISA after 72 h incubation.
Antiproliferative activity against human PBMC stimulated with ODN2006 or LPS assessed via BrdU incorporation colorimetric ELISA after 72 h incubation.
|
20674367 |
| PBMC | IC50 |
203 nM
|
Inhibition of cell viability in TSST-1-stimulated human peripheral blood mononuclear cells incubated for 72 hrs by CellTiter Glo viability assay.
Inhibition of cell viability in TSST-1-stimulated human peripheral blood mononuclear cells incubated for 72 hrs by CellTiter Glo viability assay.
|
29149330 |
In Vitro
S101 (compound 1) potently inhibits the proliferation of human Jurkat cells (IC50 = 29 nM) and human PBMC (IC50 = 70 nM), while exhibiting much lower inhibitory activity against non-hematopoietic cell lines including PC3, HEK293, NIH 3T3, A375, MDA-MB-231, and primary human keratinocytes[1].
S101 (0.01-1 μM; 72 h) specifically inhibits the proliferation of human CD3+ T cells (IC50 = ~0.1 μM) and exerts a much weaker inhibitory effect on the non-T cell components of PBMCs[1].
S101 (0.5-1 μM; 16 h) inhibits the tyrosine phosphorylation of SLP-76 and the kinase activity of ZAP-70 in human Jurkat cells in a dose-dependent manner[1].
S101 (0.5 μM; 12-24 h) induces G2 phase cell cycle arrest and low-level apoptosis in human Jurkat cells and human peripheral blood mononuclear cells (PBMC)[1].
S101 (0.5-5 μM) inhibits the proliferation of human Jurkat cells and human PBMCs without reducing IL-2 secretion[1].
S101 (0.06-4.50 μM; 72 h) inhibits the viability of SEB-stimulated human peripheral blood mononuclear cells (PBMCs) with an IC50 of 360 nM, but exerts no effect on unstimulated human PBMCs[2].
S101 (0.06-4.50 μM; 72 h) inhibits the viability of TSST-1-stimulated human peripheral blood mononuclear cells (PBMCs) with an IC50 of 203 nM, but has no effect on unstimulated human PBMCs[2].
S101 (0.06-13.5 μM; 4 h) inhibits SEB-induced secretion of TNF-α in human peripheral blood mononuclear cells (PBMCs)[2].
S101 (0.5 μM; 0.5-2 h) alters the phosphorylation levels of proteins associated with the TCR signaling pathway and the actin cytoskeleton regulatory pathway in human acute T-cell leukemia Jurkat cells. Following treatment with 0.5 μM S101 for 0.5 h, 148 phosphopeptides exhibit significant changes[2].
S101 (1 μM; 2 h) reduces CD3 expression on the surface of human peripheral blood mononuclear cells (PBMCs)[2].
S101 (0.5 μM; 1-24 h) modulates the expression of multiple aryl hydrocarbon receptor target genes in human peripheral blood mononuclear cells (PBMCs) treated with 0.5 μM S101 for 1 to 24 hours, inhibiting the expression of most targets and upregulating the expression of IL6[2].
S101 (1 μM; 0.5-6 h) retains the aryl hydrocarbon receptor in the cytoplasm of human T-cell lymphoma Karpas 299 cells[2].
S101 (24-96 h) inhibits the proliferation of human peripheral blood mononuclear cells (PBMCs) stimulated by SEB, and this inhibitory effect is detected by a reduction in BrdU incorporation, whether S101 is added simultaneously with SEB or 24 h after SEB stimulation[2].
S101 (0.5 μM; 30 h) alters gene expression in human peripheral blood mononuclear cells (PBMCs) treated with 0.5 μM for 30 h, with significant enrichment of inflammatory response pathways and altered expression of multiple AhR target genes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Karpas 299 human T-cell lymphoma cells
-
Concentration:1 μM
-
Incubation Time:0.5, 1, 2, 4, 6 h (alone); 2 h pre-incubation prior to 0.5-4 h ITE treatment; 4 h (co-incubated with ITE)
-
Result:Retained AhR in the cytosol and reduced nuclear AhR levels when administered alone.
Prevented ITE-induced CYP1B1 induction and slowed nuclear degradation of AhR when administered as a 2-hour pretreatment before ITE.
-
Cell Line:ITE-treated Jurkat human acute T-cell leukemia cells, ITE-treated Karpas 299 human T-cell lymphoma cells
-
Concentration:0.0625, 0.125, 0.25, 0.5, 1, 1.5, 2 μM
-
Incubation Time:overnight (co-incubated with ITE), followed by 4 h BrdU labeling
-
Result:Counteracted ITE-induced proliferation in Jurkat cells.
Inhibited proliferation in Karpas 299 cells treated with ITE.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (11-12-week-old female; 15-16-week-old female; sensitized with d-galactosamine prior to challenge with staphylococcal enterotoxin B or toxic shock syndrome toxin 1)[2]
-
Dosage:100 mg/kg
-
Administration:i.p.; single injection
-
Result:Rescued 100% of SEB-challenged mice when administered concurrently with toxin.
Improved survival relative to vehicle controls when administered 30 minutes after SEB.
Rescued 40% of TSST-1-challenged mice when administered 120 minutes after toxin.
Reduced blood TNF-α levels approximately 10-fold at 6 hours post-challenge in mice treated concurrently with SEB.
Lowered blood TNF-α levels to basal levels by 24 hours post-challenge in mice treated concurrently with SEB.
Chemical Information
-
CAS No. 362508-67-6
-
Molecular Weight 401.47
-
Formula C24H23N3O3
-
SMILES
N=1C(=NC(NC2=CC=C(C=C2)C)=C3C=CC=CC13)C=4C=C(OC)C(OC)=C(OC)C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Imiquimod-Induced Psoriasiform Dermatitis
Imiquimod (IMQ)-induced psoriasiform dermatitis is a widely used murine model in which topical application of IMQ, a Toll-like receptor 7 (TLR7) agonist, triggers innate immune activation in the skin and induces a psoriasis-like inflammatory cascade characterized by epidermal hyperplasia, immune cell infiltration, and cytokine production dominated by the IL-23/IL-17 axis. This inflammatory response is mediated through activation of dendritic cells and downstream induction of IL-23, IL-17A, IL-22, and related pro-inflammatory mediators, recapitulating key features of human plaque psoriasis and enabling mechanistic and therapeutic studies. The model is commonly induced using Aldara (5% IMQ cream) applied topically to murine skin, resulting in rapid onset of erythema, scaling, and thickening that can be quantified as disease severity indices and validated histologically.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- S101
- 362508-67-6
- S 101
- S-101
- Aryl Hydrocarbon Receptor
- Apoptosis
- TNF Receptor
- Karpas 299 human T-cell lymphoma cells
- aryl hydrocarbon receptor
- human PBMC
- CD3+ T cells
- Jurkat cells
- SLP-76
- actin cytoskeleton remodeling
- tumor necrosis factor alpha
- superantigen-induced toxic shock
- T cell receptor signaling
- Inhibitor
- inhibitor
- inhibit